ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Harrow Inc

Harrow Inc (HROW)

37,65
1,75
(4,87%)
Geschlossen 12 Juni 10:00PM
37,65
-0,04
(-0,11%)
Nach Börsenschluss: 10:45PM

Harrow Inc (HROW) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
37,65
( 4,87% )
Gebot
27,98
Fragen
47,62
Volumen
872.772
35,50 Tagesbereich 38,21
28,5401 52-Wochen-Bereich 54,85
Marktkapitalisierung
Handelsende
35,90
Handelsbeginn
35,95
Letzte Trade
6
@
37.65
Letzter Handelszeitpunkt
Finanzvolumen
US$ 32.399.056
VWAP
37,122
Durchschnittliches Volumen (3 Mio.)
US$ 761.345
Ausgegebene Aktien
37.275.107
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-82,33
Gewinn pro Aktie (EPS)
-0,4
Erlöse (LTM)
268,68M
Nettogewinn (LTM)
-14,96M

Über Harrow Inc

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medication... Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Nashville, United States
Gegründet
1998
Harrow Inc is listed in the Healthcare sector of the NASDAQ with ticker HROW. The last closing price for Harrow was US$35,90. Over the last year, Harrow shares have traded in a share price range of US$ 28,5401 to US$ 54,85.

Harrow currently has 37.275.107 shares in issue. The market capitalisation of Harrow is US$1,40 billion. Harrow has a price to earnings ratio (PE ratio) of -82.33.

Option-Flow Harrow (HROW)

Gesamtfluss

Bullisch

Nettoprämie

1M

Calls / Puts

100,00%

Käuf. / Verkä.

111,11%

OTM / ITM

10,53%

Sweeps

0,00%

HROW Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
14.0812.153708668533.5737.6932.7882535434.27102265CS
48.2928.235694822929.3637.6928.875182775133.20353763CS
123.4610.119918104734.1942.1328.540173434334.65640463CS
26-12.43-24.820287539950.0854.8528.540172022339.72459709CS
526.3320.210727969331.3254.8528.540166686739.32364659CS
15617.1483.568990736220.5159.237.657226529.54107263CS
26028.54313.2821075749.1159.235.442544426.53598018CS

HROW - Frequently Asked Questions (FAQ)

What is the current Harrow Inc share price?
The current share price of Harrow Inc is US$ 37,65
How many Harrow Inc shares are in issue?
Harrow Inc has 37.275.107 shares in issue
What is the market cap of Harrow Inc?
The market capitalisation of Harrow Inc is USD 1,4B
What is the 1 year trading range for Harrow Inc share price?
Harrow Inc has traded in the range of US$ 28,5401 to US$ 54,85 during the past year
What is the PE ratio of Harrow Inc?
The price to earnings ratio of Harrow Inc is -82,33
What is the cash to sales ratio of Harrow Inc?
The cash to sales ratio of Harrow Inc is 4,6
What is the registered address of Harrow Inc?
The registered address for Harrow Inc is 1A Burton Hills Boulevard, Nashville, Tennessee, 37215
What is the Harrow Inc website address?
The website address for Harrow Inc is www.harrow.com
Which industry sector does Harrow Inc operate in?
Harrow Inc operates in the Pharmaceuticals sector

HROW Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen